bioMérieux S.A. Sees Growth in Short Interest

bioMérieux S.A. (OTCMKTS:BMXMF - Get Free Report) experienced a notable rise in short interest during the month of November. As of November 30th, the total short interest reached 139,000 shares, reflecting an increase of 6.6% compared to the 130,400 shares reported on November 15th. With an average trading volume of 100 shares, this leads to a current short-interest ratio of 1,390.0 days.

Analysts Set New Price Targets

In another development, UBS Group upgraded bioMérieux shares to a "strong-buy" rating in a research report issued on August 22nd.

Get Our Latest Stock Analysis on BMXMF

bioMérieux Stock Performance

During midday trading on Friday, shares of OTCMKTS:BMXMF increased by 0.9%, rising by $0.93 to reach $107.03. A total of 140 shares were traded, while the average trading volume stands at 337 shares. The stock has a 50-day moving average price of $108.32 and a 200-day moving average price of $107.55. Over the past year, bioMérieux has seen a low of $93.50 and a high of $122.52.

About bioMérieux

bioMérieux SA is involved in developing and producing in vitro diagnostic solutions aimed at diagnosing infectious diseases across regions such as the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Their product offerings include systems that analyze biological samples—such as blood, saliva, and urine—to diagnose a range of infectious diseases, including those caused by bacteria, parasites, and viruses. Additionally, the company focuses on microbiological control for production environments, particularly in the food, pharmaceutical, and cosmetic industries.

Featured Articles

• Five stocks we like better than bioMérieux
• Short Selling: How to Short a Stock
• Dave & Buster’s: Is It Time to Make Another Play on This Stock?
• P/E Ratio Calculation: How to Assess Stocks
• Why Hershey Stock Has More Room to Run Despite Takeover Rejection
• NYSE Stocks Give Investors a Variety of Quality Options
• Texas Instruments: The Old-School Tech Titan Still Delivering

This instant news alert was generated using narrative science technology and financial data to provide readers with the latest updates.

Investment Consideration for bioMérieux

Before making an investment in bioMérieux, it's crucial to be informed. Analysts from various Wall Street firms recommend stocks daily based on their assessments. While bioMérieux boasts a "Strong Buy" rating, other analysts suggest that there are five stocks that may present better investment opportunities.

Explore these five recommended stocks for potential investments.

bioMérieux, stocks, shortinterest